Vor Biopharma (NASDAQ:VOR)announces that the U.S. FDA has granted Fast Track designation to VOR33, the company’s lead engineered hematopoietic stem cell ((eHSC)) therapeutic candidate for the treatment of acute myeloid leukemia (AML).
Fast Track designation is intended to facilitate development and expedite review of products designed to treat serious and life-threatening conditions with unmet medical needs.
Therapeutic candidates receiving Fast Track designation may be eligible for priority review and accelerated approval if certain conditions are met.
The company highlighted that it remains on-track to report VOR33’s initial clinical data in the first half of 2022.